IKNA Ikena Oncology Inc.

FDA Catalyst Company
4
+0.35  (+10%)
Previous Close 3.65
Open 3.75
52 Week Low 2.83
52 Week High 21.1816
Market Cap $144,653,164
Shares 36,163,291
Float 23,443,010
Enterprise Value $-66,734,450
Volume 36,761
Av. Daily Volume 189,667
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Credit Suisse Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/13/2022
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/13/2022
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 12/23/2021
Credit Suisse Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 08/13/2021
Jefferies Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/20/2021
William Blair Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/20/2021
Credit Suisse Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/20/2021

Latest News

  1. IK-175 clinical trial combination expansion cohort in patients with urothelial carcinoma advanced to Stage 2 based on tolerability and preliminary anti-tumor activity

    First patients dosed in our first-in-human clinical trial of IK-930 targeting TEAD in patients with advanced solid tumors with Hippo pathway genetic alterations

    Established VHIO partnership, expanding access to world-class researchers, novel capabilities, and diverse patient sample banks with applicability across Hippo, RAS, and additional discovery programs

    Continued executive team evolution, including appointment of Chief Financial Officer and Head of Corporate Development Jotin Marango, MD, PhD

    BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc…

    View Full Article
  2. Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, today announced the appointment of Maude Tessier, PhD, as Chief Business Officer. Dr. Tessier brings over 16 years of company building experience with a multi-disciplinary background in business development, corporate strategy, corporate communications, IP management, and portfolio and program management in public and private biotechnology, pharmaceutical and academic organizations.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220503005370/en/

    (Photo: Business Wire)

    (Photo: Business Wire)

    "We are very pleased to welcome Maude to the Seismic leadership team. Seismic is in a period of significant…

    View Full Article
  3. BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA), a targeted oncology company forging new territory in patient-directed cancer treatment, and the Vall d'Hebron Institute of Oncology (VHIO) today announced an alliance to enable generation and exploration of tumor and biomarker-specific data derived from specific patient populations. The resulting research from this partnership will inform the further development of novel cancer therapies, including the ongoing programs in the Hippo and RAS pathways being developed by Ikena. VHIO, located in Barcelona, Spain, is a leading comprehensive cancer research center of excellence with an extensive biobank of patient tumor samples, along with deep expertise in preclinical…

    View Full Article
  4. BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will be presenting two trial-in-progress posters at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The presentations will include overviews of the clinical trials for Ikena's novel TEAD inhibitor, IK-930, and aryl hydrocarbon receptor (AHR) antagonist, IK-175. Both posters will be presented by the trials' investigators.

    Session Title: Poster Session/Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
    Session Date/Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT

    Abstract Title: A phase 1, first-in-human…

    View Full Article
  5. BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the appointment of Jotin Marango, M.D., Ph.D., to Chief Financial Officer (CFO) and Head of Corporate Development. The addition of Dr. Marango, a seasoned expert with nearly 15 years of industry experience, comes at a pivotal time as Ikena expands its targeted oncology programs and corporate development efforts.

    "Jotin embodies the ideal qualities we look for in leadership at Ikena. He is passionate about advancing treatments for patients in need, and his drive is augmented by his accomplished and unique background across multiple verticals in the…

    View Full Article
View All Ikena Oncology Inc. News